Therapies that are being used with fewer side effects
There are a number of clinics
that use a combination of alternative and conventional therapies. For a
list of some of these clinics, go to our webpage
devoted to this.
Low dose chemotherapy
is being used by a number of clinics, including Revici,
Rational , Klinik
St George, Northern Health, Immune
Institute, and more. The chemo can be targeted to a particular organ
or administered in lower doses, thus side effects are reduced.
There is a company CellControl
out of Munich that specialize in the diagnosis and therapy of
tumor diseases. Their main product ChemoSelect® is
an innovative chemosensitivity test procedure: Through tests performed on
tissue samples, it permits predicting the on probable success of a
particular chemotherapy before that therapy is even started. It helps
determine an appropriate therapy for the individual patient. In
addition, ThermoSelect® permits determining the
effectiveness of hyperthermia in both, the presence or absence of
cytostatics. You could have your doctor contact them. Their website
Loma Linda University uses proton beam therapy for treating cancers
and tumors. This technology directs with precision where radiation
goes, so even brain tumors can be treated. In addition lung and prostate
cancers have been treated successfully using this treatment, as well as
localized cancers of the brain, eye, head and neck, spinal cord, lung,
abdomen, pelvis, and for noncancerous disorders, such as some forms
of macular degeneration of the eye, arteriovenous malformations in the
brain, and benign brain tumors. There are few side effects. More precise
beam delivery increases the probability of disease control and reduces
radiation received by normal tissues. Their website is http://www.llu.edu/proton/
and they can be reached by calling (800) 872-1212 or emailing physician
ST1 571, also known as
Glivac is a cancer
pill that is being used to treat chronic myelogenous leukemia (CML),
and may be effective in treating certain types of brain, specifically
glioblastoma, and stomach cancers, especially gastrointestinal stromal
tumors, a rare cancer of the digestive system's connective tissue..
STI-571 is a part of a growing group of molecularly
targeted treatments in which drugs are designed to treat diseases with
specific genetic changes. It
blocks a signal that the abnormal protein sends out, preventing the
abnormal growth and production of other cancerous cells.
The drug STI-571
is now in clinical trials for glioblastoma, a kind of brain tumor, and
for gastrointestinal stromal tumors and leukemia under a new agreement
between the National Cancer Institute and Novartis Pharmaceuticals. Go to our clinical
trials page to link to websites giving information on these trials, or
go to http://www.cancer.gov/clinicaltrials/digestpage/gleevec.
The drug is scheduled to
receive FDA approval soon.
If you are aware of other
therapies that would not be considered alternative, but have fewer side
effects than traditional cancer therapies, or clinics that use these
therapies, please email our webmaster
so we can research these.